Needle array assembly and method for delivering therapeutic agents
A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.
1. A method of evaluating one or more candidate agents, wherein at least one of the one or more candidate agents is a drug, comprising: introducing the one or more candidate agents to one or more positions in a solid tissue, and; evaluating effectiveness of the candidate agents on the solid tissue, wherein the introducing step is in vivo, and wherein the solid tissue is a tumor.
2. A method of evaluating one or more candidate agents, wherein at least one of the one or more candidate agents is a drug, comprising: introducing the one or more candidate agents to one or more positions in a solid tissue, and; evaluating effectiveness of the candidate agents on the solid tissue, wherein the introducing step is performed using a device comprising one or more needles, and wherein the solid tissue is a tumor.
3. The method of claim 2 , wherein the needles are arranged in an array.
4. The method of claim 2 , wherein the one or more needles are configured for passive delivery of the one or more candidate agents.
5. The method of claim 4 , wherein the device comprises needles with micropits over their surfaces.
6. The method of claim 4 , wherein the device comprises needles made from porous material.
7. The method of claim 4 , wherein at least one of the needles is charged with a candidate agent by immersion in the agent.
8. The method of claim 2 , wherein each of the needles is configured to deliver the one or more agents to spatially defined locations along parallel axes in the solid tissue.
9. The method of claim 2 , wherein each of the needles is configured to deliver the one or more agents in a column-shaped region coaxial with respect to the delivery axis.
10. The method of claim 2 , wherein each of the needles comprises a plurality of ports.
11. The method of claim 10 , wherein the plurality of ports are sized and positioned to deliver a substantially equal amount of fluid.
12. The method of claim 1 or 2 , wherein the introducing step comprises delivering an amount of the candidate agent to the solid tissue that is less than 1 μL per needle.
13. The method of claim 2 , wherein the needles are close-ended.
14. The method of claim 2 , wherein the introducing comprises delivering, with the device, a first agent to a plurality of positions within the solid tissue.
15. The method of claim 2 , wherein the introducing comprises delivering, with the device, a plurality of different agents to a plurality of different positions within the solid tissue.
16. The method of claim 1 or 2 , wherein each of the one or more candidate agents is introduced in an amount that is less than a minimal dose required to produce a detectable effect in an adult or in an amount that is undetectable outside the solid tissue.
17. The method of claim 1 or 2 , further comprising introducing one or more indicators of efficacy into the solid tissue.
18. The method of claim 1 , wherein the evaluating step comprises detecting a degree of permeation of the one or more candidate agents through the solid tissue.
19. The method of claim 1 , wherein the evaluating step comprises assessing efficacy, activity or toxicity of the one or more candidate agents on the solid tissue.
20. The method of claim 2 , further comprising performing the method in a plurality of patient samples.
21. The method of claim 1 or 2 , wherein the drug is a chemotherapeutic.
22. The method of claim 1 or 2 , wherein the drug is a preclinical or clinical drug.